14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Hold
Today CTIC ranks #4707 as hold candidate. Get a Free Stock at Robinhood
Stronger Stock

CTI BioPharma Corp. Stock Forecast NASDAQ:CTIC

$2.25 (5.63%)

Volume: 1M

Closed: Jan 19, 2022

Hollow Logo Score: 0.146

CTI BioPharma Corp. Stock Forecast

$2.25 (5.63%)

Volume: 1M

Closed: Jan 19, 2022

Score Hollow Logo 0.146

CTI BioPharma Corp. Company Profile

3101 Western Avenue

Seattle WA 98121



Industry: Biotechnology

Sector: Healthcare

CTI BioPharma Corp.


CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreements with the University of Vermont, S*BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE